Special Issue "The Impact of Extracellular Vesicles in Cancer Progression and Diagnosis"
Deadline for manuscript submissions: closed (15 October 2020) | Viewed by 13900
2. i3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal
Interests: cancer drug resistance; cancer multidrug resistance; intercellular transfer of drug resistance mediated by Extracellular Vesicles (EVs); new approaches to overcome drug resistance; drug-efflux pumps; escape from apoptosis; autophagy; metabolic alterations associated with drug resistance; tumour-microenvironment interactions; cancer stem cells; microRNAs; biomarkers of minimal residual disease and of drug resistance
Special Issues, Collections and Topics in MDPI journals
Special Issue in Molecules: Counteracting Drug Resistant Mechanisms in Cancer
Special Issue in Cancers: Extracellular Vesicles in Cancer Progression and Drug Resistance
Special Issue in Molecules: Bioactive Molecules as Multidrug Resistance Modulators
Special Issue in Cancers: New Diagnostic and Therapeutic Tools Against Multidrug Resistant Tumors (STRATAGEM Special Issue, EU-COST CA17104)
Special Issue in Cancers: New Diagnostic and Therapeutic Tools against Multidrug Resistant Tumors 2.0 (STRATAGEM Special Issue, EU-COST CA17104)
Special Issue in Molecules: Bioactive Molecules as Multidrug Resistance Modulator
This Special Issue of Cancers aims to bring together timely reviews and original research articles on the impact of Extracellular Vesicles on cancer progression and on cancer patient’s diagnosis. Topics may include but are not exclusively limited to studying the: i) impact of EVs in cancer progression and drug resistance; ii) role of EVs in the bi-directional intercellular communication between cancer cells and the tumor microenvironment; iii) cargo of EVs and their release, intercellular transfer and uptake; iv) search for EV-associated biomarkers of cancer diagnosis or prognosis.
Prof. Dr. M. Helena Vasconcelos
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Extracellular vesicles
- cancer progression
- hallmarks of cancer
- cancer drug resistance
- intercellular communication
- EV-associated biomarkers of cancer diagnosis
- EV-associated biomarkers of cancer prognosis
- EV-associated biomarkers of minimal residual disease